US 12,227,586 B2
Anti-CLDN4/anti-CD137 bispecific antibody
Yoshiyuki Tenda, Tokyo (JP); Masatoshi Yuri, Tokyo (JP); Shigenori Yagi, Tokyo (JP); Yoshiki Satake, Tokyo (JP); Kazunori Hirayama, Tokyo (JP); Hiroki Shirai, Tokyo (JP); Hiroki Sasaki, Tokyo (JP); Fumiko Chiwaki, Tokyo (JP); and Masayuki Komatsu, Tokyo (JP)
Assigned to Astellas Pharma Inc., Tokyo (JP); and National Cancer Center, Tokyo (JP)
Appl. No. 18/556,606
Filed by Astellas Pharma Inc., Tokyo (JP); and National Cancer Center, Tokyo (JP)
PCT Filed Apr. 21, 2022, PCT No. PCT/JP2022/018350
§ 371(c)(1), (2) Date Oct. 20, 2023,
PCT Pub. No. WO2022/224997, PCT Pub. Date Oct. 27, 2022.
Claims priority of application No. 2021-072429 (JP), filed on Apr. 22, 2021.
Prior Publication US 2024/0209108 A1, Jun. 27, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01)] 25 Claims
 
1. An anti-CLDN4/anti-CD137 bispecific antibody comprising a heavy chain variable region and a light chain variable region of an anti-CLDN4 antibody, and a heavy chain variable region and a light chain variable region of an anti-CD137 antibody,
wherein the heavy chain variable region and the light chain variable region of the anti-CLDN4 antibody comprises:
(a) a heavy chain variable region containing a CDR1 consisting of an amino acid sequence at amino acid positions 31-35 of SEQ ID NO: 6, a CDR2 consisting of an amino acid sequence at amino acid positions 50-66 of SEQ ID NO: 6, and a CDR3 consisting of an amino acid sequence at amino acid positions 99-112 of SEQ ID NO: 6, and
(b) a light chain variable region containing a CDR1 consisting of an amino acid sequence at amino acid positions 24-35 of SEQ ID NO: 8, a CDR2 consisting of an amino acid sequence at amino acid positions 51-57 of SEQ ID NO: 8, and a CDR3 consisting of an amino acid sequence at amino acid positions 90-98 of SEQ ID NO: 8,
wherein the heavy chain variable region and the light chain variable region of the anti-CD137 antibody comprises:
(c) a heavy chain variable region containing a CDR1 consisting of an amino acid sequence at amino acid positions 31-35 of SEQ ID NO: 14, a CDR2 consisting of an amino acid sequence at amino acid positions 50-65 of SEQ ID NO: 14, and a CDR3 consisting of an amino acid sequence at amino acid positions 98-107 of SEQ ID NO: 14, and
(d) a light chain variable region containing a CDR1 consisting of an amino acid sequence at amino acid positions 23-35 of SEQ ID NO: 16, a CDR2 consisting of an amino acid sequence at amino acid positions 51-57 of SEQ ID NO: 16, and a CDR3 consisting of an amino acid sequence at amino acid positions 90-100 of SEQ ID NO: 16,
wherein the bispecific antibody comprises:
(e) an IgG antibody consisting of a heavy chain containing the heavy chain variable region and a light chain containing the light chain variable region of the anti-CLDN4 antibody (anti-CLDN4 IgG antibody), and
(f) an anti-CD137 single chain variable fragment (anti-CD137 scFv) containing the heavy chain variable region and the light chain variable region of the anti-CD137 antibody.